Natick-based Mercy BioAnalytics, a company that focuses on advancing extracellular vesicle-based liquid biopsies for the early detection of cancer, has raised $41M in Series A funding. The round was led by Novalis LifeSciences, with participation from Sozo Ventures, Hatteras Venture Partners, iSelect Fund, American Cancer Society BrightEdge, Broadway Angels, Labcorp and Bruker.
The company aims to use the funds to advance the development and commercialization of its Halo test for high-risk lung cancer screening, its lead clinical indication, and to advance clinical programs in additional indications, including ovarian cancer.
Led by CEO Dawn Mattoon, PhD., Mercy BioAnalytics is a biotechnology company that leverages a Halo liquid biopsy platform to interrogate abundant, blood-based extracellular vesicles that carry cancer signatures from their parent cells. The platform is designed to detect Stage I cancer, when it is most treatable, and improve the quality of life for cancer patients and their families. Mercy’s primary focus is on the early detection of ovarian and lung cancers
The Series A funding raised by Mercy BioAnalytics is a testament to the company’s innovative approach to cancer detection and its potential to significantly impact cancer patients’ lives. With the funds raised, Mercy BioAnalytics is poised to continue advancing its groundbreaking research in liquid biopsies and to bring the benefits of early cancer detection to patients across the country.
